Advertisement
Screener

Protagenic Therapeutics, Inc.\new (PTIX) Foreign Currency Transaction Gain (Loss), before Tax

1.5 / 5 stars · 9/30 Roast Me

Protagenic Therapeutics, Inc.\new Foreign Currency Transaction Gain (Loss), before Tax

Protagenic Therapeutics, Inc.\new (PTIX) reported Foreign Currency Transaction Gain (Loss), before Tax of -$6.63 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2018-04-02.

Discontinued › Income Statement › Other Income

us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2018-04-02

  • Protagenic Therapeutics, Inc.\new foreign currency transaction gain (loss), before tax for the quarter ending 2016-12-31 was $17.00, a 99.98% decline year-over-year.
  • Protagenic Therapeutics, Inc.\new foreign currency transaction gain (loss), before tax for the quarter ending 2016-09-30 was -$43.00.
  • Protagenic Therapeutics, Inc.\new foreign currency transaction gain (loss), before tax for the quarter ending 2016-06-30 was $543.00.
  • Protagenic Therapeutics, Inc.\new foreign currency transaction gain (loss), before tax for the quarter ending 2016-03-31 was -$7.14K, a 158.88% decline year-over-year.
  • Protagenic Therapeutics, Inc.\new foreign currency transaction gain (loss), before tax for fiscal 2016 was -$6.63K, a 150.62% decline from fiscal 2015.
  • Protagenic Therapeutics, Inc.\new foreign currency transaction gain (loss), before tax for fiscal 2015 was $13.09K.
Period endForeign Currency Transaction Gain (Loss), before Tax 3 monthForeign Currency Transaction Gain (Loss), before Tax 6 monthForeign Currency Transaction Gain (Loss), before Tax 9 monthForeign Currency Transaction Gain (Loss), before Tax 12 month
2016-12-31$17.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02
-$26.00
derived: sum of 2 quarters · filed 2018-04-02
$517.00
derived: sum of 3 quarters · filed 2018-04-02
-$6.63K
10-K · filed 2018-04-02
2016-09-30-$43.00
10-Q · filed 2017-11-13
$500.00
derived: sum of 2 quarters · filed 2017-11-13
-$6.64K
10-Q · filed 2017-11-13
$81.11K
derived: sum of 4 quarters · filed 2017-11-13
2016-06-30$543.00
10-Q · filed 2017-08-08
-$6.60K
10-Q · filed 2017-08-08
$81.15K
derived: sum of 3 quarters · filed 2017-08-08
$2.52K
derived: sum of 4 quarters · filed 2017-08-08
2016-03-31-$7.14K
10-Q · filed 2017-05-15
$80.61K
derived: sum of 2 quarters · filed 2017-05-15
$1.97K
derived: sum of 3 quarters · filed 2017-05-15
-$6.18K
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$87.75K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-05-08
$9.12K
derived: sum of 2 quarters · filed 2017-05-08
$959.00
derived: sum of 3 quarters · filed 2017-05-08
$13.09K
10-K/A · filed 2017-05-08
2015-09-30-$78.64K
10-Q · filed 2016-11-17
-$86.79K
derived: sum of 2 quarters · filed 2016-11-17
-$74.66K
10-Q · filed 2016-11-17
2015-06-30-$8.16K
10-Q · filed 2016-08-15
$3.97K
10-Q · filed 2016-08-15
2015-03-31$12.13K
10-Q · filed 2016-07-25
2014-12-31-$10.43K
8-K/A · filed 2016-07-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Aditxt, Inc. (ADTX)United States$0.000B
Rafael Holdings, Inc. (RFL)United States$0.000B-0.00